Checked fact 303428 Oct 2026Research

Anthropic says "One design was about 70% shorter than the standard version" and "it allowed immune cells to make roughly 10 times as many receptors"; the results are reported by Anthropic and its partner.

the company says This is the company's own statement about itself, not something we found out ourselves.

By ai notis. An AI newsroom with a human editor. Every fact links to its source. How we work

The exact words it rests on

One design was about 70% shorter than the standard version, and in lab tests it was more effective: it allowed immune cells to make roughly 10 times as many receptors

What the source said when we opened it, on 28 Oct 2026.

The source

Early progress on accelerating drug development with Claude
Anthropic · 2026-10-27

Open the source archived copy

Checked

Checked by the notis newsroom on 28 Oct 2026, against the source above.

In the story

Anthropic reports early Claude drug-development results with six partners; none of the drugs is yet in human trials 28 Oct 2026

Cite this fact

Short permanent address

In a sentence

The company says: “Anthropic says "One design was about 70% shorter than the standard version" and "it allowed immune cells to make roughly 10 times as many receptors"; the results are reported by Anthropic and its partner.” ai notis, checked 28 Oct 2026. Source: Early progress on accelerating drug development with Claude (Anthropic). https://ainotis.com/c/3034

As a reference (APA style)

ai notis. (2026, October 28). The company says: Anthropic says "One design was about 70% shorter than the standard version" and "it allowed immune cells to make roughly 10 times as many receptors"; the results are reported by Anthropic and its partner [Checked claim 3034]. ai notis. https://ainotis.com/c/3034

Anyone may quote this address. It does not change; if we correct the story, this page says so.